...generic competition [in Guatemala and elsewhere] has been effective in bringing down prices...[and] making life-extending treatment available...this access is now being threatened...[by “free trade agreements” with the USA] that limit generic competition and the ability of countries...to protect public health and ensure access to medicines...Treating fewer people means condemning others to premature death. [refers to GlaxoSmithKline, Bristol-Myers Squibb]